Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide versus placebo in transfusion-dependent del(5q) myelodysplastic syndromes
2005-000454-73Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lenalidomide in myelodysplastic syndrome (MDS) (3 arms), sponsored by Celgene Corporation. Primary endpoint: RBC transfusion independence for at least 26 weeks. Started Feb 2005; status: completed.
02
Drugs
lenalidomide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2005-000454-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000454-73.